STAT

SABA-only rescue is incomplete. It’s time to consider an alternative approach

AIRSUPRA® (albuterol/budesonide) represents a paradigm shift in asthma rescue as the first and only FDA-approved anti-inflammatory rescue inhaler for asthma that is designed to address both ...
Hosted on MSN

Virtual trial shows combo rescue inhaler nearly halves severe asthma attacks

Findings from a first-of-its-kind virtual trial in pulmonary medicine, conducted at Rutgers and many other institutions, suggest adding an inhaled corticosteroid to rescue therapy could sharply reduce ...
Morningstar

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and ...
Seeking Alpha

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

Full results published in the New England Journal of Medicine and presented at ATS 2025 International Conference BATURA builds upon the previous Phase III MANDALA and DENALI trials and in totality, ...